Neuroplasticity in Parkinson's Disease

Description

The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.

Conditions

Parkinson, Parkinson Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this project is to increase our understanding of the early state and temporal evolution of neuroplastic changes in the cortex and subthalamic nucleus (STN) of people with PD, and the relationship of these changes to the emergence and expression of PD motor and non-motor signs. Neurophysiological biomarkers derived from this work may be important for the early detection and prediction of progression of disease. They can also provide the means to assess the efficacy of interventions designed to prevent or slow disease progression.

Plasticity of Motor Systems in Early Stage Parkinson's Disease

Neuroplasticity in Parkinson's Disease

Condition
Parkinson
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of idiopathic PD, as determined by a movement disorders neurologist in accordance with the PD Society Brain Bank diagnostic criteria
  • * Not receiving levodopa or dopamine agonist to treat PD (at baseline)
  • * Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters Healthy Controls
  • * Age- (+/- 3 years) and sex-matched to participants with PD
  • * Able to ambulate independently without the use of an assistive device (e.g. cane) for 50 meters
  • * Dementia diagnosis and/or a University of California Brief Assessment of Capacity to Consent (UBACC) score and MacCAT-CR score indicating impaired capacity to consent
  • * History of musculoskeletal disorders that significant affect movement of lower or upper limbs as determined at the time of enrollment
  • * History of bipolar disorder, post-traumatic stress disorder or major depressive disorder
  • * Other significant neurological disorders that may affect participation or performance in the study
  • * Implanted DBS or other neurosurgeries to treat PD
  • * Pregnancy
  • * History of seizures, epilepsy, stroke, multiple sclerosis, or traumatic brain injury
  • * Intracranial metallic or magnetic devices (e.g. cochlear implant, deep brain stimulator)
  • * Pacemaker or any implanted device
  • * History of surgery on blood vessels, brain, or heart
  • * Unexplained, recurring headaches or concussion within the last six months
  • * Severe hearing impairment

Ages Eligible for Study

21 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Minnesota,

Study Record Dates

2028-11-09